Your session is about to expire
← Back to Search
Veliparib + Lapatinib for Breast Cancer
Study Summary
This trial will study the effectiveness of two drugs, Veliparib and Lapatinib, for treating metastatic triple negative breast cancer.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My heart's electrical cycle is normal and I don't have conditions that could make it unsafe.I have not used anthracyclines or taxanes for my cancer.I do not have any severe illnesses that could interfere with the study.My breast cancer is confirmed to be at stage IV.Women who are pregnant or breastfeeding cannot participate in the study because there might be risks to the baby if the mother is treated with the study drug.Your platelet count is at least 100,000 per microliter.I have recovered from side effects of previous treatments and do not have severe nerve damage.I am taking bisphosphonates, but my bone lesions can't be used to measure my cancer's progress.My brain cancer has not worsened in the last 3 months, and I haven't taken steroids or seizure medicines for 3 months.I have cancer spread to my brain but also have a measurable tumor outside my brain.I have had no more than two treatments for my cancer since it spread, or I haven't had any but was treated with anthracyclines and taxanes before it spread.I finished my radiation therapy more than 21 days ago.Your liver function tests should not be too high, unless you have liver cancer that has spread.My organ and bone marrow functions are normal.My kidney function, measured by creatinine levels or clearance, is within the required range.Your hemoglobin level is 9 mg/dL or higher.Metastatic lesions that can only be seen on a PET scan.I am 19 years old or older.I am not currently on chemotherapy for metastatic disease.I have not had cancer, except for certain skin cancers, in the last 5 years.I am able to understand and give informed consent.I agree to a biopsy if my cancer has spread and it's safe to do so.I stopped chemotherapy 3 weeks ago.I can take care of myself but might not be able to do heavy physical work.My doctor expects me to live more than 12 weeks.I have seizures that are not controlled by medication.I have a history of HIV or Hepatitis B.My tumor is not driven by HER-2, estrogen, or progesterone, and I don't have BRCA mutations.You must have a visible and measurable lesion that can be accurately measured.If you can have a baby, a test must show that you are not pregnant before you can join the study.Your body has enough infection-fighting white blood cells.Your bilirubin levels are within the normal range set by the hospital.Your heart's ejection fraction must be at least 50%.
- Group 1: Combination of Veliparib + Lapatinib
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many participants will be accepted in this clinical exploration?
"Unfortunately, recruitment for this research has already concluded. It was initially posted on September 1st 2014 and last reviewed on February 25th 2022. However, 2354 medical trials are presently recruiting participants with breast cancer while 42 studies related to the combination of Veliparib + Lapatinib currently require patients."
What maladies can be alleviated with the Veliparib + Lapatinib combination therapy?
"Combination of Veliparib + Lapatinib is a viable solution for postmenopausal women, breast cancer patients and those seeking advance directives."
Are there any preceding research examining the effects of Veliparib and Lapatinib administered together?
"Currently, 11 Combination of Veliparib + Lapatinib clinical trials are in Phase 3 with 42 ongoing studies. Though Lexington is the epicentre for these investigations, there exist 4371 sites globally conducting related research."
Are investigators currently adding participants to this research endeavor?
"This medical trial is no longer accepting new patients. Initially posted on September 1st, 2014 and last updated February 25th 2022, participants should look elsewhere for clinical trials. At present, 2354 studies are recruiting individuals with a diagnosis of breast cancer while 42 separate investigations need volunteers to combine veliparib + lapatinib medications."
Share this study with friends
Copy Link
Messenger